Important Note
- Recall Info:Ortho Biotech Products plans to discontinue sales and distribution of the itraconazole injection formulation. The final manufactured batch will expire in February 2008, and product depletion is anticipated by year-end 2007. This action was not based on safety-related issues.
General Dosage Information
- capsules and oral solution are not interchangeable
Allergic bronchopulmonary aspergillosis
- 200 mg ORALLY twice daily
Aspergillosis, Invasive, in high-risk patients; Prophylaxis
- salvage therapy, 200 mg ORALLY every 12 hours
Aspergillosis, Invasive, salvage therapy
- 200 mg ORALLY twice daily (guideline dosing)
- (capsules) 200 mg ORALLY once daily up to a MAX of 200 mg ORALLY twice daily (manufacturer dosing)
- (capsules) life-threatening situations; 200 mg ORALLY 3 times daily for 3 days (loading dose), followed by 200 mg ORALLY once daily up to a MAX of 200 mg ORALLY twice daily; continue for at least 3 months and until evidence of clinical and laboratory improvement (manufacturer dosing)
Blastomycosis
- (mild-to-moderate pulmonary or disseminated disease), loading dose of 200 mg ORALLY 3 times daily for 3 days, followed by 200 mg ORALLY once or twice daily for 6 to 12 months (guideline dosing)
- (moderately severe to severe pulmonary or disseminated disease) stepdown therapy (after initial therapy with amphotericin B), loading dose of 200 mg ORALLY 3 times daily for 3 days, followed by 200 mg ORALLY twice daily for 6 to 12 months (guideline dosing)
- (CNS disease) stepdown therapy (after initial treatment with a lipid formulation amphotericin B), 200 mg ORALLY 2 or 3 times daily for at least 1 year and until resolution of cerebrospinal fluid abnormalities (guideline dosing)
- (capsules) 200 mg ORALLY once daily up to a MAX of 200 mg ORALLY twice daily (for progressive fungal disease); continue for at least 3 months and until evidence of clinical and laboratory improvement (manufacturer dosing)
- (capsules) life-threatening situations; a loading dose of 200 mg ORALLY 3 times daily for 3 days, followed by 200 mg ORALLY once daily up to a MAX of 200 mg ORALLY twice daily (for progressive fungal disease); continue for at least 3 months and until evidence of clinical and laboratory improvement (manufacturer dosing)
Candidal vulvovaginitis - HIV infection
- (oral solution), uncomplicated, 200 mg ORALLY daily for 3 to 7 days
Candidiasis of the esophagus
- (oral solution) 100 to 200 mg SWISH/SWALLOW daily for minimum of 3 weeks and for 2 weeks following symptom resolution (manufacturer dosing)
- (oral solution, fluconazole-refractory disease) 200 mg ORALLY daily for 14 to 21 days (guideline dosing)
Candidiasis of the esophagus - HIV infection
- (oral solution) 100 to 200 mg SWISH/SWALLOW daily for minimum of 3 weeks and for 2 weeks following symptom resolution (manufacturer dosing) OR 200 mg ORALLY daily for 14 to 21 days (guideline dosing)
Coccidioidomycosis
- 200 mg ORALLY 2 or 3 times daily; up to 800 mg ORALLY daily in 4 divided doses for disseminated infection
- (uncomplicated acute coccidioidal pneumonia) 200 mg ORALLY once or twice daily for 3 to 6 months
Coccidioidomycosis; Prophylaxis - HIV infection
- 200 mg ORALLY twice daily; continue until CD4+ counts are at least 250 cells/mcL for 6 months
Coccidioidomycosis - HIV infection
- 200 mg ORALLY 3 times daily for 3 days, then 200 mg ORALLY twice daily; continue long-term suppressive therapy with 200 mg ORALLY twice daily
Cryptococcal meningitis - HIV infection
- consolidation, 200 mg ORALLY twice daily for 8 weeks or until CD4+ count is at least 200 cells/mcL for more than 6 months due to HAART (guideline dosing)
- maintenance, 200 mg ORALLY daily for life or until immune reconstitution due to HAART (guideline dosing)
Cryptococcosis
- (mild-to-moderate pulmonary disease in nonimmunosuppressed patients) alternative therapy, 200 mg/day ORALLY for 6 to 12 months
Febrile neutropenia, Empiric antifungal therapy
- 200 mg ORALLY twice daily (guideline dosing)
Histoplasmosis, Central Nervous System
- stepdown therapy after initial therapy with liposomal amphotericin B, 200 mg ORALLY 2 or 3 times daily for at least 1 year and until resolution of cerebrospinal fluid abnormalities
Histoplasmosis, Central Nervous System - HIV infection
- stepdown therapy after initial therapy with liposomal amphotericin B for 4 to 6 weeks, 200 mg ORALLY 2 to 3 times daily for at least 1 year and until resolution of abnormal CSF findings (guideline dosing)
- chronic suppressive therapy, 200 mg ORALLY once daily until CD4+ counts are greater than 150 cells/mcL in patients with negative Histoplasma blood cultures, serum antigen less than 2 units, and who have received at least 1 year of treatment and at least 6 months of HAART (guideline dosing)
Histoplasmosis, Disseminated
- (mild to moderate disease) 200 mg ORALLY 3 times daily for 3 days, followed by 200 mg ORALLY twice daily for at least 12 months (guideline dosing)
- (moderately severe to severe disease) stepdown therapy after initial therapy with amphotericin B (deoxycholate or lipid formulation), 200 mg ORALLY 3 times daily for 3 days, followed by 200 mg ORALLY twice daily for a total of at least 12 months (guideline dosing)
- lifelong suppressive therapy, 200 mg ORALLY once daily (immunosuppressed patients and in patients who relapse despite appropriate therapy) (guideline dosing)
- (capsules) 200 mg ORALLY once daily up to a MAX of 200 mg ORALLY twice daily (for progressive fungal disease); continue for at least 3 months and until evidence of clinical and laboratory improvement (manufacturer dosing)
- (capsules) life-threatening situations, a loading dose of 200 mg ORALLY 3 times daily for 3 days, followed by 200 mg ORALLY once daily up to a MAX of 200 mg ORALLY twice daily (for progressive fungal disease); continue for at least 3 months and until evidence of clinical and laboratory improvement (manufacturer dosing)
Histoplasmosis, Disseminated, nonmeningeal - HIV infection
- mild to moderate disease, 200 mg ORALLY 3 times daily for 3 days, then 200 mg ORALLY twice daily for at least 12 months (guideline dosing)
- stepdown therapy after initial therapy with liposomal amphotericin B for moderately severe to severe disease, 200 mg ORALLY 3 times daily for 3 days, then 200 mg ORALLY twice daily for a total of at least 12 months (guideline dosing)
- chronic suppressive therapy, 200 mg ORALLY once daily until CD4+ counts are greater than 150 cells/mcL in patients with negative Histoplasma blood cultures, serum antigen less than 2 units, and who have received at least 1 year of treatment and at least 6 months of HAART (guideline dosing)
- (capsules) 200 mg ORALLY once daily up to a MAX of 200 mg ORALLY twice daily (for progressive fungal disease); continue for at least 3 months and until evidence of clinical and laboratory improvement (manufacturer dosing)
- (capsules) life-threatening situations, a loading dose of 200 mg ORALLY 3 times daily for 3 days, then 200 mg ORALLY once daily up to a MAX of 200 mg ORALLY twice daily (for progressive fungal disease); continue for at least 3 months and until evidence of clinical and laboratory improvement (manufacturer dosing)
Histoplasmosis; Prophylaxis - HIV infection
- 200 mg ORALLY daily until CD4+ counts are more than 150 cells/mcL for 6 months in patients receiving antiretroviral therapy
Histoplasmosis; Prophylaxis - Patient immunosuppressed
- 200 mg ORALLY once daily
HIV infection - Oropharyngeal candidiasis
- (oral solution) 200 mg SWISH/SWALLOW daily for 1 to 2 weeks
- (oral solution, fluconazole-refractory disease) 100 mg SWISH/SWALLOW twice daily (manufacturer dosing) OR at least 200 mg ORALLY daily (guideline dosing)
HIV infection - Oropharyngeal candidiasis, Recurrent; Prophylaxis
- (oral solution) 200 mg ORALLY daily until the CD4+ count is at least 200 cells/mcL
Onychomycosis due to dermatophyte
- (tablets) toenails; 200 mg ORALLY once daily for 12 weeks
- (capsules) fingernails only; 200 mg ORALLY twice daily for 1 week, off drug for 3 weeks, repeat 200 mg ORALLY twice daily for 1 week
- (capsules) toenails with or without fingernail involvement; 200 mg ORALLY once daily for 12 weeks
Oropharyngeal candidiasis
- (oral solution) fluconazole-refractory disease, 200 mg ORALLY daily for 7 to 14 days (guideline dosing)
- (oral solution) 200 mg SWISH/SWALLOW daily for 1 to 2 weeks, or 100 mg SWISH/SWALLOW twice daily for fluconazole-refractory disease (manufacturer dosing)
Pulmonary aspergillosis, Chronic (cavitary or necrotizing)
- salvage therapy, 200 mg ORALLY twice daily
Pulmonary histoplasmosis
- (mild-to-moderate acute pulmonary histoplasmosis) 200 mg ORALLY 3 times daily for 3 days followed by 200 mg ORALLY once or twice daily for 6 to 12 weeks (guideline dosing)
- (moderately severe to severe acute pulmonary histoplasmosis) stepdown therapy after initial therapy with amphotericin B (deoxycholate or lipid formulation), 200 mg ORALLY 3 times daily for 3 days followed by 200 mg ORALLY twice daily for a total of 12 weeks (guideline dosing)
- (chronic cavitary pulmonary histoplasmosis) 200 mg ORALLY 3 times daily for 3 days followed by 200 mg ORALLY once or twice daily for at least 12 months; up to 18 to 24 months may be necessary (guideline dosing)
- (capsules) 200 mg ORALLY once daily up to a MAX of 200 mg ORALLY twice daily (for progressive fungal disease); continue for at least 3 months and until evidence of clinical and laboratory improvement (manufacturer dosing)
- (capsules) life threatening situations, a loading dose of 200 mg ORALLY 3 times daily for 3 days, followed by 200 mg ORALLY once daily up to a MAX of 200 mg ORALLY twice daily (for progressive fungal disease); continue for at least 3 months and until evidence of clinical and laboratory improvement (manufacturer dosing)
Sporotrichosis
- cutaneous or lymphocutaneous sporotrichosis, loading dose of 200 mg ORALLY 3 times daily for 3 days, followed by 200 mg ORALLY daily or 200 mg ORALLY twice daily in patients not responding; continue for 2 to 4 weeks after all lesions have healed
- osteoarticular or less severe pulmonary sporotrichosis, loading dose of 200 mg ORALLY 3 times daily for 3 days, followed by 200 mg ORALLY twice daily for least 12 months
- meningeal, disseminated or pulmonary sporotrichosis, stepdown therapy after amphotericin B therapy, loading dose of 200 mg ORALLY 3 times daily for 3 days, followed by 200 mg ORALLY twice daily; give to complete total treatment duration of 12 months

Conazole (Itraconazole - Capsule 100 mg) – Full Drug Info.

SCIENTIFIC NAME

INDICATIONS

CLASSIFICATION

MECHANISM OF ACTION

CLINICAL USE

ADULT DOSE

PEDIATRIC DOSE

ADMINISTRATION

CONTRAINDICATIONS

SIDE EFFECTS

PREGNANCY

MAJOR INTERACTIONS

MINOR INTERACTIONS

SCIENTIFIC NAME

INDICATIONS

CLASSIFICATION

MECHANISM OF ACTION

CLINICAL USE

ADULT DOSE

PEDIATRIC DOSE

ADMINISTRATION

CONTRAINDICATIONS

SIDE EFFECTS

PREGNANCY

MAJOR INTERACTIONS

MINOR INTERACTIONS